Sunitinib Side Effects — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Benign sunitinib pigmentation from its yellow active compound
Sunitinib and its active metabolite are yellow and can cause benign skin discolouration when bilirubin and liver tests are normal. Conjugated hyperbilirubinaemia caused by sunitinib-related cholestatic injury: normal bilirubin and liver tests argue strongly against jaundice from cholestasis. Unconjugated hyperbilirubinaemia caused by sunitinib-related immune haemolysis: haemolysis would raise bilirubin and produce anaemia or haemolytic markers. Cutaneous carotenaemia caused by treatment-related hypothyroidism: carotenaemia has a different distribution and is not the characteristic sunitinib colour effect. Diffuse haemosiderin deposition caused by repeated transfusion exposure: iron deposition develops in a different exposure setting and is not bright yellow.
Reference: SUTENT UK summary of product characteristics (Current UK SmPC, accessed July 2026): https://www.medicines.org.uk/emc/product/7968/smpc